Blood Plasma Derivatives Market By Product Type (Albumin, Immunoglobulin, Coagulation Factor Concentrates, Protease Inhibitors, Others), By End-User Industry (Hospitals, Diagnostic Laboratories, Clinics, Research Institutions, Others), By Technology (Cryoprecipitation, Liquid Chromatography, Immunoaffinity Chromatography, Others), and By Application (Hemophilia Treatment, Immune Deficiency Diseases, Trauma & Burns, Liver Diseases, Others); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Blood Plasma Derivatives Market was valued at USD 30.6 billion in 2023 and will surpass USD 54.1 billion by 2030; growing at a CAGR of 8.5% during 2024 - 2030. The blood plasma derivatives market has witnessed significant growth over the years, fueled by the increasing demand for therapies used in treating a variety of life-threatening conditions, such as hemophilia, immune deficiency diseases, and trauma-related illnesses. Plasma-derived products, including albumin, immunoglobulin, and coagulation factor concentrates, are crucial for treating a range of complex disorders, especially in critical care and chronic diseases. As healthcare systems evolve, the blood plasma derivatives market is benefiting from advances in biotechnology, improved manufacturing processes, and increased awareness of the therapeutic benefits these products offer. With a rising global population and an increase in healthcare needs, the market for blood plasma derivatives continues to expand, particularly in emerging regions. Albumin Segment is Largest Owing to Its Widespread Use in Critical Care Albumin remains the largest product segment in the blood plasma derivatives market, primarily due to its widespread use in a variety of medical conditions. This plasma-derived protein is crucial for the treatment of burns, shock, hypoalbuminemia, and liver diseases. Its role in maintaining oncotic pressure and stabilizing blood volume in patients undergoing surgeries or suffering from trauma makes it indispensable in critical care settings. Hospitals and clinics around the world rely on albumin to stabilize patients in intensive care units (ICUs), especially in emergency care and during major surgeries. The demand for albumin has been consistently rising, driven by its proven efficacy in treating conditions like hypoalbuminemia associated with cirrhosis, nephrotic syndrome, and burns. As a result, albumin holds a dominant market share, representing a key revenue generator within the blood plasma derivatives sector. The ongoing development of new formulations and delivery methods for albumin further supports its widespread use, ensuring its continued dominance in the market. Hospital End-User Segment is Largest Due to Growing Demand for Plasma-Based Therapies Hospitals are the largest end-user segment in the blood plasma derivatives market, as these healthcare facilities account for a significant portion of the plasma-derived product consumption. Hospitals are major consumers of plasma-derived products like immunoglobulins and albumin, owing to their critical role in treating acute and chronic conditions. Plasma-derived products are used to treat conditions such as trauma, liver diseases, immune deficiency diseases, and hemophilia, all of which require advanced and immediate care that hospitals can provide. The increasing prevalence of conditions like hemophilia and immune deficiency diseases has led to a surge in the demand for plasma derivatives in hospital settings. Hospitals are equipped with the necessary infrastructure and expertise to manage the storage and administration of these sensitive and high-cost products. As such, hospitals will continue to represent the largest end-user segment in the blood plasma derivatives market. Liquid Chromatography Technology is Fastest Growing Due to Its High Precision Liquid chromatography (LC) technology is the fastest-growing segment in the blood plasma derivatives market, owing to its ability to precisely separate and analyze components of plasma for the production of derivatives. Liquid chromatography is essential for the purification and analysis of blood plasma-derived proteins, ensuring high-quality products for therapeutic use. The growth of liquid chromatography is fueled by its increasing use in both research and production processes, where it plays a critical role in optimizing plasma product yields and purity. The growing demand for more advanced and accurate testing methods to produce plasma-derived therapeutics has led to a shift toward liquid chromatography. Additionally, advancements in automated systems and the development of new chromatographic techniques have made liquid chromatography more efficient, further accelerating its adoption in the blood plasma derivatives market. Hemophilia Treatment Application is Largest Due to Rising Prevalence Hemophilia treatment is the largest application segment in the blood plasma derivatives market, driven by the increasing global prevalence of hemophilia and other coagulation disorders. Coagulation factor concentrates, which are essential for treating hemophilia, represent a major portion of the market due to the high demand for these products in managing bleeding episodes in patients. Hemophilia, a hereditary disorder that affects blood clotting, requires frequent and ongoing treatment with factor concentrates, and the growing awareness of these therapies has led to greater adoption. As more patients are diagnosed and receive lifelong treatment, the demand for blood plasma derivatives, particularly coagulation factor concentrates, continues to rise. In addition, advancements in recombinant therapies and more efficient production methods are enhancing the accessibility and affordability of these critical treatments. The rise in hemophilia diagnoses and the expansion of healthcare infrastructure in developing nations are expected to contribute significantly to the growth of this application segment. North America is Largest Region Owing to Advanced Healthcare Infrastructure North America holds the largest market share in the blood plasma derivatives market, primarily driven by the region’s advanced healthcare infrastructure, high healthcare expenditure, and established medical facilities. The United States, in particular, has a significant demand for blood plasma derivatives due to the high prevalence of chronic diseases, including hemophilia, liver disorders, and immune deficiency diseases. The region’s healthcare providers and pharmaceutical companies also contribute significantly to the production and development of plasma-derived therapies, reinforcing the market's dominance in North America. In addition to the robust healthcare system, the region benefits from the presence of leading companies in the blood plasma derivatives market and a well-established regulatory framework that ensures the quality and safety of plasma-derived products. North America is expected to continue leading the market, although the demand for blood plasma derivatives is also expected to rise in emerging regions like Asia-Pacific, where healthcare advancements are rapidly improving. Leading Companies and Competitive Landscape The blood plasma derivatives market is highly competitive, with several global players dominating the market. Key companies include CSL Limited, Grifols, Baxter International, Octapharma, and Kedrion Biopharma. These companies are engaged in the production, distribution, and research of plasma-derived therapies, which are critical for treating a wide range of medical conditions. Many of these companies have strategic partnerships, collaborations, and acquisitions to expand their product portfolios and geographic reach. The competitive landscape is shaped by ongoing innovation, regulatory approvals, and investments in improving plasma collection and processing technologies. Companies are also focusing on expanding their presence in emerging markets, where rising healthcare needs are driving demand for plasma-derived therapies. With increasing competition and the ongoing development of new treatments, the blood plasma derivatives market is expected to experience continued growth in the coming years. Recent Developments: • Grifols launched a new immunoglobulin product for patients with primary immunodeficiency, aiming to increase treatment options for the rare disease. • CSL Behring announced the completion of a significant expansion to its manufacturing facilities in North America, enhancing production capacity for immunoglobulin. • Takeda Pharmaceutical secured approval from regulatory authorities in Europe for a new albumin therapy, aiming to strengthen its leadership in plasma-derived therapies. • Octapharma acquired a state-of-the-art fractionation facility to boost production and improve the efficiency of its plasma-derived products, particularly immunoglobulins. • Biotest AG entered a strategic collaboration with a biotechnology firm to enhance the development of new coagulation factor concentrates targeting rare blood disorders. List of Leading Companies: • Grifols • CSL Behring • Takeda Pharmaceutical Company • Octapharma • Baxter International Inc. • Biotest AG • Kedrion Biopharma • LFB Group • Shanghai RAAS Blood Products Co. • Emergent BioSolutions Inc. • China Biologic Products • Sanquin • Ferring Pharmaceuticals • Blood Plasma Technologies • Hi-Tech BioSolutions Report Scope: Report Features Description Market Size (2023) USD 30.6 Billion Forecasted Value (2030) USD 54.1 Billion CAGR (2024 – 2030) 8.5% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Blood Plasma Derivatives Market By Product Type (Albumin, Immunoglobulin, Coagulation Factor Concentrates, Protease Inhibitors), By End-User Industry (Hospitals, Diagnostic Laboratories, Clinics, Research Institutions), By Technology (Cryoprecipitation, Liquid Chromatography, Immunoaffinity Chromatography), and By Application (Hemophilia Treatment, Immune Deficiency Diseases, Trauma & Burns, Liver Diseases) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Grifols, CSL Behring, Takeda Pharmaceutical Company, Octapharma, Baxter International Inc., Biotest AG, Kedrion Biopharma, LFB Group, Shanghai RAAS Blood Products Co., Emergent BioSolutions Inc., China Biologic Products, Sanquin, Ferring Pharmaceuticals, Blood Plasma Technologies, Hi-Tech BioSolutions Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements